Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India

Asian Journal of Pharmaceutics

Volumn 8, Issue 3, 2014, Pages 178-182

  Dhivya, P ^a   Swathy, G ^b   Pal, Siddhartha ^c  

^a ANNA UNIVERSITY   (India)

^b SWAMY VIVEKANANDHA COLLEGE OF PHARMACY   (India)

^c Periyar College of Pharmaceutical Sciences for Girls   (India)

Author keywords

Antihypertensive drugs; beta blockers; cost effectiveness

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DRUG COST; HOSPITAL; HUMAN; HYPERTENSION; INDIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTISPECIALTY HOSPITAL; PATIENT SELECTION; PRESCRIPTION; PULSE RATE; SYSTOLIC BLOOD PRESSURE;

EID: 84906997742     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.139182     Document Type: Article

References (18)

1. Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich). 2003;53 Suppl 2:3-13.
2. Gupta R, Rastogi P, Hariprasad D, Mathur B, Bhardwaj AK, Coronary Heart Diseases and Risk Factors in Rural Populations of India. South Asian J Prev Cardiol. Available from: http://www.sajprevcardiology.com/vol7/vol7-4/coronaryheart.htm. [Last accessed on 2014 Jun 28].
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997;349:1269-76.
4. Redwood H. Hypertension, society, and public policy. Eur Heart J 2007;9:B13-8.
5. Pierdomenico SD, Di Nicola M, Esposito AL, Di Mascio R, Ballone E, Lapenna D, et al. Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 2009;22:842-7.
6. Arenas-Guzman R, Tosti A, Hay R, Haneke E, National Institue for Clinical Excellence. Pharmacoeconomics-an aid to better decision-making. J Eur Acad Dermatol Venereol 2005;19 Suppl 1:34-9.
7. Surendra G, Abasaheb B, Patil S, Kushare S. Pharmacoeconomics: A Review. Asian J Pharm Clin Res 2009;2:15-26.
8. Walley T, Davey P. Pharmacoeconomics: A challenge for clinical pharmacologists. Br J Clin Pharmacol 1995;40:199-202.
9. Fletcher A. Economics of hypertension control: A statement by the world hypertension league. J Hum Hypertens 1994;8:789-95.
10. Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. Clin Exp Hypertens 1998;20:833-46.
11. Sur G, Sur M, Kudor-Szabadi M, Sur L, Sporis D. Arterial hypertension Prevalence of risk factors and morbid associations that increase cardiovascular risk. J Clin Med Int J Hypertens 2011;5:34-40.
12. By Y, Mr NG, Ag U. Prevalence, awareness, treatment, and control of hypertension in rural areas of davanagere. Indian J Community Med 2010;35:138-41.
13. Girerd X, Giral P. Risk stratification for the prevention of cardiovascular complications of hypertension. Curr Med Res Opin 2004;20:1137-42.
14. Catanzaro DF, Frishman WH. Angiotensin receptor blockers for management of hypertension. South Med J 2010;103:669-73.
15. Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoysich AM, Ryschon K. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994;16:88-102.
16. Dias da Costa JS, Fuchs SC, Olinto MT, Gigante DP, Menezes AM, Macedo S, et al. Cost-effectiveness of hypertension treatment: A population-based study. Sao Paulo Med J 2002;120:100-4.
17. Ulasi III, Ijoma CK, Onwubere BJ, Arodiwe E, Onodugo O, Okafor C. High prevalence and low awareness of hypertension in a market population in enugu, Nigeria. Int J Hypertens. 2011;2011:869675.
18. Girerd X1, Giral P. Risk stratification for the prevention of cardiovascular complications of hypertension. Curr Med Res Opin, 2004;20 :1137-42.